EvaluatePharma® Yearbook

Summary

Benchmark a Changing Market

In a fast-changing pharmaceutical market it is vital to be able to measure company performance easily and accurately - find out which companies are winning in the areas that count and which are suffering in changing circumstances. The new EvaluatePharma Yearbook gives you the information that you need, in context.

The Yearbook provides information and data of the highest quality, taken directly from the EvaluatePharma database and it will enable you to:

• Benchmark company revenue and expenditure
• Analyse company performance
• Assess mergers and acquisitions
• Understand patent expiry issues
• Match R&D spend to performance
• Analyse sales by therapy area, licensing, acquisitions etc
• Analyse winners and losers by therapy area

All of the detailed information in the Yearbook is put in context by explanations of the new pharmaceutical market place, how it works and how companies perform within it.

The Yearbook provides detailed information about the top 150 companies, including:

• Revenue
• Income
• Growth
• R&D expenditure
• M&A activity
• Patent expiry
• Staffing levels
• Expenditure

With 41 tables of detailed EvaluatePharma information this 130 page report is edited by former Scrip Magazine Journalist Jacky Law.

It is essential reading for everybody in the pharmaceutical market from senior executives and corporate strategists, through marketing and sales departments to market analysts and pharmaceutical outsourcing companies.

Contents

• List of tables for EvaluatePharma Yearbook 2008
• Chapter 1: Company performance, 2006-2007
  • 1.1: Total Rx & OTC sales
  • 1.2: Net income
  • 1.3: Normalised net income
  • 1.4: Market capitalisation
  • 1.5: Price-earnings ratio
  • 1.6: Cash in the bank
• Chapter 2. Performance analysis
  • 2.1.1: Growth rankings for total Rx & OTC sales: companies earning > $10 billion
  • 2.1.2: Growth rankings for normalised net income: companies earning > $10 billion
  • 2.1.3: Growth rankings for market cap and share price: companies earning > $10 billion
  • 2.1.4: Rankings of price-earnings ratios: companies earning > $10 billion
  • 2.1.5: Mergers and acquisitions: companies earning > $10 billion
  • 2.2.1: Growth rankings for total Rx & OTC sales: companies earning $1 billion - $10 billion
  • 2.2.2: Growth rankings for normalised net income: companies earning $1 billion - $10 billion
  • 2.2.3: Growth rankings for market cap and share price: companies earning $1 billion - $10 billion
  • 2.2.4: Rankings of price-earnings ratios: companies earning $1 billion - $10 billion
  • 2.2.5: Mergers and acquisitions: companies earning $1 billion - $10 billion
  • 2.3.1: Growth rankings for total Rx & OTC sales: companies earning < $10 billion
  • 2.3.2: Growth rankings for normalised net income: companies earning < $10billion
  • 2.3.3: Growth rankings for market cap and share price: companies earning < $10billion
  • 2.3.4: Rankings of price-earnings ratios: companies earning < $10billion
  • 2.3.5: Mergers and acquisitions: companies earning < $10 billion
• Chapter 3. Operational efficiency
  • 3.1 Employee numbers
  • 3.2 R&D spend and as a proportion of sales, by business sector
  • 3.3 SG&A spend and as a proportion of sales, by business sector
  • 3.4 CoGs spend and as a proportion of sales, by business sector
• Chapter 4. Shifting sands
  • 4.1: US sales growth, 2000-2007 & US sales as a % of pharma sales for the global majors, 2000-2007
  • 4.2: Pharma sales by therapeutic area, 2000-2007
    • 4.2.1: Therapeutic sales as a % of Rx & OTC sales for global majors, 2000-2007
  • 4.3: Generics company sales, 2006-2007
  • 4.4: Speciality company sales, 2006-2007
• Chapter 5. Strategic thinking
  • 5.1: Worldwide sales by technology, 2000-2007
    • 5.1.1: Sales by technolgy for global majors, 2000-2007
  • 5.2: Worldwide sales by strategy, 2000-2007
    • 5.2.1: Sales by strategy for global majors, 2000-2007
  • 5.3: Worldwide sales by patent risk, 2000-2007
    • 5.3.1: Sales by patent risk for global majors, 2000-2007
• Chapter 6. Market developments
  • 6.1: FDA approvals and research products abandoned, 2003-2007
  • 6.2: US patent expiries of products with US sales of more than $100 million (2007-2011) showing US annual sales, 2007-2012
  • 6.3: Major licensing deals in 2007
• Appendix 1
  • Total pharmaceutica sales (2007) showing sales from Rx, OTC, total Rx & OTC, alliance/co-promotion, royalty & licensing and other pharma (including bulk sales)
• Appendix 2.1
  • Top companies by market capitalisation
• Appendix 2.2
  • Top companies by sector
• Appendix 2.3
  • Top companies by country
• Appendix 3
  • Company profiles